LIVIVO - Search results -

Search results

Result 1 - 10 of total 25

Search options

Article ; Online: The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology.

Yiu, Z Z N / Mason, K J / Smith, C H / Griffiths, C E M

2020 Volume 183, Issue 6, Page(s) 981–983

MeSH term(s)	Biological Factors ; Biological Products ; Dermatologists ; Dermatology ; Humans ; Immunologic Factors
Chemical Substances	Biological Factors ; Biological Products ; Immunologic Factors
Language	English
Publishing date	2020-12-14
Publishing country	England
Document type	Editorial ; Research Support, Non-U.S. Gov't
ZDB-ID	80076-4
ISSN	1365-2133 ; 0007-0963
ISSN (online)	1365-2133
ISSN	0007-0963
DOI	10.1111/bjd.19536
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.23: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Risk of cancer in patients with psoriasis on biological therapies: a systematic review.

Peleva, E / Exton, L S / Kelley, K / Kleyn, C E / Mason, K J / Smith, C H

The British journal of dermatology

2017 Volume 178, Issue 1, Page(s) 103–113

Abstract: Background: Biological therapies are highly effective in psoriasis, but have profound effects on innate and adaptive immune pathways that may negatively impact on cancer immunosurveillance mechanisms.: Objectives: To investigate the risk of cancer in ...

Abstract	Background: Biological therapies are highly effective in psoriasis, but have profound effects on innate and adaptive immune pathways that may negatively impact on cancer immunosurveillance mechanisms. Objectives: To investigate the risk of cancer in patients with psoriasis treated with biological therapy. Methods: We searched MEDLINE, Embase, and the Cochrane Library (up to August 2016) for randomized controlled trials, prospective cohort studies and systematic reviews that reported cancer incidence in people exposed to biological therapy for psoriasis compared with a control population. Results: Eight prospective cohort studies met our inclusion criteria. All the evidence reviewed related to tumour necrosis factor inhibitors (TNFi) with the exception of one study on ustekinumab. An increased risk of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma, was reported with TNFi compared with both a general United States population and a rheumatoid arthritis population treated with TNFi. No evidence for increased risk of cancers (reported as all cancers, lymphoma, melanoma, prostate, colorectal and breast cancer) other than NMSC was identified. Conclusions: There were important limitations to the studies identified including choice of comparator arms, inadequate adjustment for confounding factors and failure to account for latency periods of cancer. There remains a need for ongoing pharmacovigilance in relation to cancer risk and biological therapy; the NMSC signal requires further investigation to determine the risk specifically attributable to biological therapy using prospectively collected data with adjustment for known NMSC risk factors.
MeSH term(s)	Adalimumab/adverse effects ; Adult ; Biological Products/adverse effects ; Dermatologic Agents/adverse effects ; Epidemiologic Methods ; Etanercept/adverse effects ; Female ; Humans ; Infliximab/adverse effects ; Male ; Middle Aged ; Neoplasms/chemically induced ; Psoriasis/drug therapy ; Risk Factors ; Ustekinumab/adverse effects
Chemical Substances	Biological Products ; Dermatologic Agents ; Infliximab (B72HH48FLU) ; Ustekinumab (FU77B4U5Z0) ; Adalimumab (FYS6T7F842) ; Etanercept (OP401G7OJC)
Language	English
Publishing date	2017-12-18
Publishing country	England
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	80076-4
ISSN	1365-2133 ; 0007-0963
ISSN (online)	1365-2133
ISSN	0007-0963
DOI	10.1111/bjd.15830
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.23: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR.

Mason, K J / Burden, A D / Barker, J N W N / Lunt, M / Ali, H / Kleyn, C E / McElhone, K / Soliman, M M / Green, A C / Griffiths, C E M / Reynolds, N J / Ormerod, A D

Journal of the European Academy of Dermatology and Venereology : JEADV

2021 Volume 35, Issue 8, Page(s) e498–e501

MeSH term(s)	Humans ; Psoriasis/complications ; Psoriasis/epidemiology ; Skin Neoplasms/epidemiology ; Ustekinumab
Chemical Substances	Ustekinumab (FU77B4U5Z0)
Language	English
Publishing date	2021-03-29
Publishing country	England
Document type	Letter
ZDB-ID	1128828-0
ISSN	1468-3083 ; 0926-9959
ISSN (online)	1468-3083
ISSN	0926-9959
DOI	10.1111/jdv.17230
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3492: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 413: Show issues

Order via subito

Details ▾

Article ; Online: Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies.

Mason, K J / Burden, A D / Barker, J N W N / Lunt, M / Ali, H / Kleyn, C E / McElhone, K / Soliman, M M / Green, A C / Griffiths, C E M / Reynolds, N J / Ormerod, A D

Journal of the European Academy of Dermatology and Venereology : JEADV

2021 Volume 35, Issue 8, Page(s) e496–e498

MeSH term(s)	Biological Products ; Carcinoma, Squamous Cell/drug therapy ; Dermatologic Agents/therapeutic use ; Humans ; Psoriasis/drug therapy
Chemical Substances	Biological Products ; Dermatologic Agents
Language	English
Publishing date	2021-05-03
Publishing country	England
Document type	Letter
ZDB-ID	1128828-0
ISSN	1468-3083 ; 0926-9959
ISSN (online)	1468-3083
ISSN	0926-9959
DOI	10.1111/jdv.17282
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3492: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 413: Show issues

Order via subito

Details ▾

Article: The carbon emissions of selected airlines and aircraft types in three geographic markets

Miyoshi, C / Mason, K. J

Journal of air transport management Vol. 15, No. 3 , p. 138-147

2009 Volume 15, Issue 3, Page(s) 138–147

Author's details	C. Miyoshi; K. J. Mason
Keywords	Luftverkehr ; Treibhausgas-Emissionen ; Umweltbelastung ; Berechnung ; Wissenschaftliche Methode ; Luftverkehrsgesellschaft ; Großbritannien ; EU-Staaten ; Atlantischer Raum
Language	English
Size	graph. Darst.
Publisher	Elsevier
Publishing place	Amsterdam [u.a.]
Document type	Article
ZDB-ID	1208154-1
Database	ECONomics Information System

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Neuromuscular scoliosis: a case of the pediatric patient in the adult ICU.

Mason, K J

Critical care nursing quarterly

1998 Volume 21, Issue 2, Page(s) 64–80

Abstract: Neuromuscular scoliosis can be a problem in children with underlying neuromuscular conditions such as cerebral palsy, spina bifida, and muscular dystrophy. A comprehensive preoperative assessment is essential to provide comprehensive postoperative care. ... ...

Abstract	Neuromuscular scoliosis can be a problem in children with underlying neuromuscular conditions such as cerebral palsy, spina bifida, and muscular dystrophy. A comprehensive preoperative assessment is essential to provide comprehensive postoperative care. Surgical procedures to correct neuromuscular scoliosis include anterior spinal fusion, posterior spinal fusion, or a combined anterior-posterior spinal fusion. Postoperative problems can include respiratory failure, hemodynamic instability, neurovascular compromise, and pain control. With an understanding of the developmental status of these patients, pediatric patients can be safely managed in an adult ICU.
MeSH term(s)	Adolescent ; Adult ; Age Factors ; Child ; Critical Care/methods ; Humans ; Intensive Care Units ; Neuromuscular Diseases/complications ; Nursing Assessment/methods ; Pediatric Nursing/methods ; Perioperative Care/methods ; Scoliosis/etiology ; Scoliosis/nursing ; Scoliosis/surgery
Language	English
Publishing date	1998-08
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	639095-x
ISSN	0887-9303
ISSN	0887-9303
DOI	10.1097/00002727-199808000-00008
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2298: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Yiu, Z Z N / Mason, K J / Hampton, P J / Reynolds, N J / Smith, C H / Lunt, M / Griffiths, C E M / Warren, R B

The British journal of dermatology

2020 Volume 183, Issue 2, Page(s) 294–302

Abstract: Background: Real-world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies.: Objectives: (i) To assess the relative drug survival of ... ...

Abstract	Background: Real-world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies. Objectives: (i) To assess the relative drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis. (ii) To investigate predictors of biologic drug survival. Methods: A prospective cohort study was performed in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) between November 2007 and August 2019. We performed survival analysis and fitted a flexible parametric survival model for biologic discontinuation due to ineffectiveness. Results: In total 9652 patients were included: 5543 starting on adalimumab (57·4%), 991 on secukinumab (10·3%) and 3118 on ustekinumab (32·3%). The overall drug survivals of adalimumab, secukinumab and ustekinumab in year 1 were 0·78 [95% confidence interval (CI) 0·77-0·79], 0·88 (95% CI 0·86-0·91) and 0·88 (95% CI 0·87-0·89), respectively. The adjusted hazard ratios (adjHRs) for discontinuation of adalimumab and secukinumab compared with ustekinumab were 2·11 (95% CI 1·76-2·54) and 0·67 (95% CI 0·40-1·11), respectively. The presence of psoriatic arthritis predicted for survival in the adalimumab and secukinumab cohorts (adjHR 0·67, 95% CI 0·51-0·88 and 0·70, 95% CI 0·40-1·24, respectively), but for discontinuation in the ustekinumab cohort (adjHR 1·42, 95% CI 1·12-1·81). Previous exposure to biologic therapies predicted for discontinuation in the ustekinumab and secukinumab cohorts (adjHR 1·54, 95% CI 1·26-1·89 and 1·49, 95% CI 0·91-2·45, respectively) and for survival in the adalimumab cohort (adjHR 0·71, 95% CI 0·55-0·92). Conclusions: Secukinumab and ustekinumab have similar sustained drug survival, while adalimumab has a lower drug survival in patients with psoriasis. Psoriatic arthritis and previous biologic experience were predictors with differential effects between the biologic therapies. What is already known about this topic? There is conflicting evidence over the real-world drug survival of secukinumab in patients with psoriasis. Data from registries to date suggest that secukinumab has a lower drug survival than that reported from clinical trials. What does this study add? This study found that secukinumab and ustekinumab had similar sustained drug survival in the real world, while the drug survival of adalimumab was lower, suggesting that the real-world drug survival of secukinumab is higher than previously reported. We found that psoriatic arthritis and previous biologic experience had differential effects on drug discontinuation in the three biologic cohorts. These predictors may help patients and clinicians choose the most appropriate biologic therapy.
MeSH term(s)	Adalimumab ; Antibodies, Monoclonal, Humanized ; Biological Products ; Cohort Studies ; Dermatologists ; Etanercept ; Humans ; Immunologic Factors ; Pharmaceutical Preparations ; Prospective Studies ; Psoriasis/drug therapy ; Treatment Outcome ; Ustekinumab
Chemical Substances	Antibodies, Monoclonal, Humanized ; Biological Products ; Immunologic Factors ; Pharmaceutical Preparations ; secukinumab (DLG4EML025) ; Ustekinumab (FU77B4U5Z0) ; Adalimumab (FYS6T7F842) ; Etanercept (OP401G7OJC)
Language	English
Publishing date	2020-03-30
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80076-4
ISSN	1365-2133 ; 0007-0963
ISSN (online)	1365-2133
ISSN	0007-0963
DOI	10.1111/bjd.18981
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.23: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.

Rungapiromnan, W / Mason, K J / Lunt, M / McElhone, K / Burden, A D / Rutter, M K / Warren, R B / Griffiths, C E M / Ashcroft, D M

Journal of the European Academy of Dermatology and Venereology : JEADV

2019 Volume 34, Issue 4, Page(s) 769–778

Abstract: Background: The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.: Objectives: To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in ... ...

Abstract	Background: The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. Objectives: To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in patients with chronic plaque psoriasis treated with adalimumab, etanercept or ustekinumab in a large prospective cohort. Methods: Prospective cohort study examining the comparative risk of major CVEs was conducted using the British Association of Dermatologists Biologics and Immunomodulators Register. The main analysis compared adults with chronic plaque psoriasis receiving ustekinumab with tumour necrosis-α inhibitors (TNFi: etanercept and adalimumab), whilst the secondary analyses compared ustekinumab, etanercept or methotrexate against adalimumab. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using overlap weights by propensity score to balance baseline covariates among comparison groups. Results: We included 5468 biologic-naïve patients subsequently exposed (951 ustekinumab; 1313 etanercept; and 3204 adalimumab) in the main analysis. The secondary analyses also included 2189 patients receiving methotrexate. The median (p25-p75) follow-up times for patients using ustekinumab, TNFi, adalimumab, etanercept and methotrexate were as follows: 2.01 (1.16-3.21), 1.93 (1.05-3.34), 1.94 (1.09-3.32), 1.92 (0.93-3.45) and 1.43 (0.84-2.53) years, respectively. Ustekinumab, TNFi, adalimumab, etanercept and methotrexate groups had 7, 29, 23, 6 and 9 patients experiencing major CVEs, respectively. No differences in the risk of major CVEs were observed between biologic therapies [adjusted HR for ustekinumab vs. TNFi: 0.96 (95% CI 0.41-2.22); ustekinumab vs. adalimumab: 0.81 (0.30-2.17); etanercept vs. adalimumab: 0.81 (0.28-2.30)] and methotrexate against adalimumab [1.05 (0.34-3.28)]. Conclusions: In this large prospective cohort study, we found no significant differences in the risk of major CVEs between three different biologic therapies and methotrexate. Additional studies, with longer term follow-up, are needed to investigate the potential effects of biologic therapies on incidence of major CVEs.
MeSH term(s)	Adalimumab/adverse effects ; Adult ; Biological Therapy/adverse effects ; Etanercept/adverse effects ; Female ; Heart Disease Risk Factors ; Humans ; Male ; Methotrexate/adverse effects ; Middle Aged ; Prospective Studies ; Psoriasis/drug therapy ; Ustekinumab/adverse effects
Chemical Substances	Ustekinumab (FU77B4U5Z0) ; Adalimumab (FYS6T7F842) ; Etanercept (OP401G7OJC) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2019-11-19
Publishing country	England
Document type	Journal Article ; Multicenter Study
ZDB-ID	1128828-0
ISSN	1468-3083 ; 0926-9959
ISSN (online)	1468-3083
ISSN	0926-9959
DOI	10.1111/jdv.16018
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3492: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 413: Show issues

Order via subito

Details ▾

Article ; Online: A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.

Yiu, Z Z N / Mason, K J / Barker, J N W N / Hampton, P J / McElhone, K / Smith, C H / Warren, R B / Griffiths, C E M / Lunt, M / Burden, A D

The British journal of dermatology

2019 Volume 181, Issue 6, Page(s) 1265–1271

Abstract: Background: Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real-world psoriasis population.: Objectives: Firstly, to investigate whether patient characteristics are ... ...

Abstract	Background: Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real-world psoriasis population. Objectives: Firstly, to investigate whether patient characteristics are associated with being included in a psoriasis RCT. Secondly, to estimate the differences in the incidence of severe adverse events (SAEs) and the response rate between RCT and real-world populations of patients on biologic therapies for psoriasis using a standardization method. Methods: Data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) were appended to individual participant-level data from two RCTs assessing ustekinumab in patients with psoriasis. Baseline variables were assessed for association of being in an RCT using a multivariable logistic regression model. Propensity score weights were derived to reweigh the registry population so that variables had the distribution of the trial population. We measured the C-statistic of the model with trial status as the dependent variable, and the risk differences in the incidence rate of SAEs in the first year and Psoriasis Area and Severity Index (PASI) after 6 months in the BADBIR cohort before and after weighting. Results: In total 6790 registry and 2021 RCT participants were included. The multivariable logistic regression model had a C-statistic of 0.82 [95% confidence interval (CI) 0.81-0.83]. The risk differences for the incidence rate of SAEs and the proportion of patients with PASI < 1.5 were 9.27 (95% CI -3.91-22.5) per 1000 person-years and 0.95 (95% CI -1.98-4.15), respectively. Conclusions: Our results suggest that RCTs of biologic therapies in patients with psoriasis are not fully representative of the real-world population, but this lack of external validity does not account for the efficacy-effectiveness gap. What's already known about this topic? Patients with psoriasis who would not be eligible for randomized controlled trials (RCTs) investigating biologic therapies have a greater risk of serious adverse events and lower treatment effectiveness than patients who would have been eligible. What does this study add? Baseline patient characteristics were shown to be predictive of whether a patient would have been eligible for enrolment in an RCT for psoriasis biologic therapy. We did not find any efficacy-effectiveness gap between the sample representative of the real-world population of patients with psoriasis and the sample representative of the RCT population. Factors outside of baseline patient characteristics, such as observer effect and higher adherence in RCTs, may be more influential in any efficacy-effectiveness gap between trial and real-world populations of patients with psoriasis.
MeSH term(s)	Adalimumab/administration & dosage ; Adalimumab/adverse effects ; Adult ; Aged ; Aged, 80 and over ; Biological Products/administration & dosage ; Biological Products/adverse effects ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/etiology ; Etanercept/administration & dosage ; Etanercept/adverse effects ; Female ; Humans ; Incidence ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; Patient Selection ; Psoriasis/diagnosis ; Psoriasis/drug therapy ; Randomized Controlled Trials as Topic/standards ; Reference Standards ; Registries/standards ; Registries/statistics & numerical data ; Research Design/standards ; Treatment Outcome ; Ustekinumab/administration & dosage ; Ustekinumab/adverse effects ; Young Adult
Chemical Substances	Biological Products ; Ustekinumab (FU77B4U5Z0) ; Adalimumab (FYS6T7F842) ; Etanercept (OP401G7OJC)
Language	English
Publishing date	2019-07-02
Publishing country	England
Document type	Comparative Study ; Journal Article
ZDB-ID	80076-4
ISSN	1365-2133 ; 0007-0963
ISSN (online)	1365-2133
ISSN	0007-0963
DOI	10.1111/bjd.17849
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.23: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy.

Yiu, Z Z N / Sorbe, C / Lunt, M / Rustenbach, S J / Kühl, L / Augustin, M / Mason, K J / Ashcroft, D M / Griffiths, C E M / Warren, R B

The British journal of dermatology

2019 Volume 180, Issue 4, Page(s) 894–901

Abstract: Background: Patients with psoriasis are often concerned about the risk of serious infection associated with systemic psoriasis treatments.: Objectives: To develop and externally validate a prediction model for serious infection in patients with ... ...

Abstract	Background: Patients with psoriasis are often concerned about the risk of serious infection associated with systemic psoriasis treatments. Objectives: To develop and externally validate a prediction model for serious infection in patients with psoriasis within 1 year of starting systemic therapies. Methods: The risk prediction model was developed using the British Association of Dermatologists Biologic Interventions Register (BADBIR), and the German Psoriasis Registry PsoBest was used as the validation dataset. Model discrimination and calibration were assessed internally and externally using the C-statistic, the calibration slope and the calibration in the large. Results: Overall 175 (1·7%) out of 10 033 participants from BADBIR and 41 (1·7%) out of 2423 participants from PsoBest developed a serious infection within 1 year of therapy initiation. Selected predictors in a multiple logistic regression model included nine baseline covariates, and starting infliximab was the strongest predictor. Evaluation of model performance showed a bootstrap optimism-corrected C-statistic of 0·64 [95% confidence interval (CI) 0·60-0·69], calibration in the large of 0·02 (95% CI -0·14 to 0·17) and a calibration slope of 0·88 (95% CI 0·70-1·07), while external validation performance was poor, with C-statistic 0·52 (95% CI 0·42-0·62), calibration in the large 0·06 (95% CI -0·25 to 0·37) and calibration slope 0·36 (95% CI -0·24 to 0·97). Conclusions: We present the first results of the development of a multivariable prediction model. This model may help patients and dermatologists in the U.K. and the Republic of Ireland to identify modifiable risk factors and inform therapy choice in a shared decision-making process.
MeSH term(s)	Adult ; Biological Products/adverse effects ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/methods ; Female ; Follow-Up Studies ; Germany/epidemiology ; Hospitalization/statistics & numerical data ; Humans ; Immunosuppressive Agents/adverse effects ; Infections/epidemiology ; Infections/immunology ; Infections/therapy ; Ireland/epidemiology ; Logistic Models ; Male ; Middle Aged ; Models, Biological ; Pharmacovigilance ; Prospective Studies ; Psoriasis/complications ; Psoriasis/drug therapy ; Psoriasis/immunology ; Registries/statistics & numerical data ; Risk Assessment/methods ; Risk Factors ; United Kingdom/epidemiology
Chemical Substances	Biological Products ; Immunosuppressive Agents
Language	English
Publishing date	2019-01-15
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Validation Study
ZDB-ID	80076-4
ISSN	1365-2133 ; 0007-0963
ISSN (online)	1365-2133
ISSN	0007-0963
DOI	10.1111/bjd.17421
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.23: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito